Form 4: Akero Therapeutics CEO Andrew Cheng Sells Shares Under 10b5-1 Trading Plan

Akero Therapeutics' CEO, Andrew Cheng, sold shares of common stock on May 12, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 12, 2025, Andrew Cheng, the President and CEO of Akero Therapeutics, sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan previously adopted on August 16, 2024.
• A total of 7,200 shares were sold at a weighted average price of $41, with prices ranging from $40.32 to $41.31.
• An additional 22,800 shares were sold at a weighted average price of $41.634, with prices ranging from $41.32 to $41.96.
• Following these transactions, Andrew Cheng directly owns 594,324 shares of Akero Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock sales by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

This is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates

Keywords

Akero Therapeutics, Andrew Cheng, stock sale, Form 4, Rule 10b5-1, insider trading, AKRO